Ahmet Adiguzel

Background/aimThere are insufficient tools to assist in the diagnosis and treatment of vestibular migraine. The aim of the study to perform the Turkish adaptation of the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI).Materials and methodsAfter language and content validity was completed, a pilot study was conducted. Exploratory and confirmatory factor analyzes were conducted to test construct validity, and as a result of validity analyses, Cronbach α internal consistency coefficient and test-retest analyzes were conducted for reliability.ResultsIn the study in which 289 participants were evaluated, the Kaiser-Meyer-Olkin coefficient was calculated as 0.903. The percentage of variance explained by the explanatory factor analysis was 67.246% and the range of factor load change was 0.433-0.828. The scale structure was tested with confirmatory factor analysis and the model was confirmed with adequate goodness of fit index values. Cronbach's α internal consistency coefficient of the scale was 0.931.ConclusionThe VM-PATHI is a valid and reliable tool for the subjective evaluation of vestibular migraine in Türkiye.

Systemic immune-inflammation index (SII) is a novel inflammatory marker and is commonly used in clinical management such as prognosis and response to therapies. In this study, the outcomes and correlations of inflammatory markers in central and peripheral facial paralysis were evaluated. The study was planned retrospectively and cross-sectionally. Totally 133 patients (group 1; 53, group 2; 80) were included in the study. The neutrophil counts were 4.7 ± 1.6 and 3.7 ± 1.6 (p=0.001), and the lymphocyte counts were 2.8 ± 0.8 and 3.3 ± 1 (p=0.007) in groups 1 and 2, respectively. While Neutrophil lymphocyte ratio (NLR) was 1.8 ± 0.9 in patients with central facial paralysis, NLR was analysed as 1.4 ± 1 in patients with peripheral facial paralysis (p=0.001). Systemic immune-inflammation index was determined as 529.5 ± 297.4 in the first group and 408.2 ± 228.1 in the second group (p=0.029). There was a positive correlation between NLR and SII (r:0.787, p

Dyslipidemia is a major atherogenic risk factor for ischemic stroke. Stroke patients tend to have high levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C). Therefore, it is noteworthy that there has been an increase in ischemic stroke cases in young and elderly individuals in recent years. This study investigated the TC/HDL-C ratio and the LDL-C/HDL-C ratio, which may be more specific and common lipid parameters in young patients with ischemic stroke. This study aimed to demonstrate the sensitivity and specificity of TC/HDL-C and LDL-C/HDL-C ratios as atherogenic markers for young adult ischemic strokes. This trial was conducted as a retrospective case—control study. A total of 123 patients (patient group) and 86 healthy individuals (control group) aged 18–50 years were randomly selected from four different hospitals. Lipid parameters and TC/HDL-C and LDL-C/HDL-C ratios were compared between these two groups. The mean age was 38.8 ± 7.3 years in patients and 37.7 ± 9 years in controls (p > 005). The HDL-C levels were 39.1 ± 10.8 mg/dL in patients and 48.4 ± 13.8 mg/dL in controls (p < 0.001). LDL-C/HDL-C ratios were 3.23 ± 1.74 and 2.38 ± 0.87, and TC/HDL-C ratios were 5.24 ± 2.31 and 4.10 ± 1.25 in the patient and control groups, respectively (p < 0.001). The LDL-C/HDL-C and TC/HDL-C cutoff values in ROC analyses were 2.61 and 4.40 respectively; the AUCs (95% CI) were determined to be 0.680 (0.608–0.753) and 0.683 (0.610–0.755) (p < 0.001), respectively. An increased risk of stroke was observed in those with a high LDL-C/HDL-C ratio (OR = 1.827; 95% CI = 1.341–2.488; p < 0.001). Our study obtained similar results when we compared the mean TC and LDL-C levels between the two groups. However, considering the TC/HDL-C and LDL-C/HDL-C ratios, it is noteworthy that there was a significant difference between the patient and control groups.

Carbamazepine may cause clinical effects such as dizziness and nystagmus. This may depend on the duration of use. The aim of this study is to measure the effect of carbamazepine monotherapy on the vestibular system electrophysiologically by using Video Head Impulse Test (VHIT) and to compare the numerical and objective data obtained between the groups. In this study, in which 55 people (110 ears) participated, Video Head Impulse Test (VHIT) was performed to evaluate the vestibulo-ocular reflex (VOR) in the epilepsy patients and a healthy control group consisting of healthy individuals. In addition, patients were analyzed in two groups to demonstrate the long-term effects of carbamazepine (10 years). Right/left lateral, anterior, posterior semi-circular canals (SCCs) VOR gains, lateral, left anterior right posterior, and right anterior right posterior gain asymmetries were measured between groups. Lateral SCCs VOR gains were 0.878±0.057 and 0.921±0.045 between the patient and healthy control groups, respectively (p=0.024). A decrease in the right and left lateral SCCs VOR gains (0.885±0.062 and 0.868±0.063) was detected in the patients (p=0.011 and p=0.001). Those using carbamazepine for >10 years had a decrease in lateral SSCs VOR gains (0.843±0.055) compared to those using the drug for 10 years).

Parkinson hastalığının tedavisindeki güncel medikal ve cerrahi stratejilerin incelendiği bu çalışmada, standart levodopa tedavisine yanıt vermeyen ileri evre hastalar için geliştirilen levodopa/karbidopa intestinal jel ve derin beyin stimülasyonu gibi yöntemler detaylandırılmaktadır. Ayrıca fiziksel egzersizin semptomlar üzerindeki olumlu etkileri ile alfa-sinükleini hedefleyen immünoterapiler, gen tedavileri ve bağırsak mikrobiyotası odaklı yaklaşımlar gibi faz aşamasındaki yenilikçi tedavi seçenekleri sunulmaktadır. Makale, hastalığın etyolojisine yönelik kişiselleştirilmiş stratejilerin ve nöroprotektif yaklaşımların gelecekteki tedavi başarısı için taşıdığı kritik önemi vurgulayarak sonuçlanmaktadır. This study examines current medical and surgical strategies in the treatment of Parkinson's Disease, detailing methods such as levodopa/carbidopa intestinal gel and deep brain stimulation for advanced-stage patients who no longer respond to standard therapies. It also presents the positive effects of physical exercise on symptoms alongside innovative phase-stage treatment options, including alpha-synuclein-targeted immunotherapies, gene therapies, and gut microbiota-focused approaches. The article concludes by emphasizing the critical importance of personalized, etiology-targeted strategies and neuroprotective approaches for the future success of Parkinson's treatment.

Purpose: The aim of this study is to analyze the utility of lipid parameters individually and the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol (LDL-C/HDL-C) ratio as a possible risk marker for intracerebral hemorrhages (ICH). Materials and Methods: This was a multicenter, retrospective case-control study that included 226 patients with ICH and 226 controls. Lipid parameters were evaluated after 12 h of fasting in patients whose ICH was confirmed by brain computed tomography, and no underlying vascular, traumatic, or metabolic cause could be found. Results: The mean LDL-C levels and mean total cholesterol (TC) levels did not differ in in the patient and control groups. The mean HDL-C levels in the patient groups were significantly lower whereas triglyceride (TG) levels were significantly higher. In the patient and control groups, LDL-C/HDL-C ratio was 2.65±1.10 and 2.94±1.13 (p=0.006), TG/HDL-C ratio was 3.60±2.72 and 4.47±3.25 (p=0.002), and TC/HDL-C ratio was 4.37±1.49 and 4.83 ± 1.56 (p=0.002), respectively. Conclusion: Increased TG and decreased HDL-C levels were found to be associated with ICHs. However LDL-C/HDL-C, TC/HDL-C, and TG/HDL-C ratios were low in the patient group. Therefore, we can conclude that these lipid ratios give clearer and more significant results in determining the risk of hemorrhage.

Objective: The effects of the COVID-19 pandemic on both the physical and psychological well-being of individuals have not yet been clearly understood. Especially during the early period of the pandemic, the most prevalent psychological effects included fear, preoccupation with health, anxiety, and feeling of loneliness caused by a general sense of uncertainty. The incidence of headache was as high as 70% among the mild COVID-19 cases. Findings from the past coronavirus outbreaks indicated that neuropsychiatric symptoms might cause a significant health burden and adversely affect the patients’ quality of life. The present study aimed to investigate the anxiety-related clinical conditions of the patients diagnosed with primary headache, who presented to the neurology polyclinic during the prolonged pandemic period. Methods: The research was designed as a two-center, prospective case-control study. Patients diagnosed with primary headache, who presented to the neurology outpatient clinic, and healthy volunteers without a primary headache diagnosis were included in the study. Data collection tools included the sociodemographic data form, Headache Impact Test, Coronavirus Anxiety Scale Short Form, and COVID-19 Disease Perception Scale. Results: Data collected from a total of 869 participants, including 408 (47%) patients diagnosed with headache and 461 (53%) healthy volunteers, were investigated. The results of the Headache Impact Test-6 suggested a severe effect on quality of life in 187 participants (45.8%) in the headache group and 73 participants (15.8%) in the Control Group (p=0.001). There was coronavirus anxiety in 59 (14.5%) participants with headache and 8 (1.7%) participants in the Control Group (p=0.001). Furthermore, the rate of coronavirus anxiety in participants that had and did not have COVID-19 was 44 (13.7%) and 22 (4.1%), respectively (p=0.001). Conclusion: The study results revealed that patients with headache and COVID-19 presented with a higher rate of coronavirus anxiety than healthy controls and those not diagnosed with COVID-19. Further studies on larger samples are necessary for investigating the long term neuropsychiatric effects of COVID-19 in individuals.